{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:26:08Z","timestamp":1783776368119,"version":"3.55.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100013103","name":"QIMR Berghofer Medical Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013103","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-001965"],"award-info":[{"award-number":["INV-001965"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blocking the transmission of parasites from humans to mosquitoes is a key component of malaria control. Tafenoquine exhibits activity against all stages of the malaria parasite and may have utility as a transmission blocking agent. We aimed to characterize the transmission blocking activity of low-dose tafenoquine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Healthy adults were inoculated with Plasmodium falciparum 3D7-infected erythrocytes on day 0. Piperaquine was administered on days 9 and 11 to clear asexual parasitemia while allowing gametocyte development. A single 50-mg oral dose of tafenoquine was administered on day 25. Transmission was determined by enriched membrane feeding assays predose and at 1, 4, and 7 days postdose. Artemether-lumefantrine was administered following the final assay. Outcomes were the reduction in mosquito infection and gametocytemia after tafenoquine and safety parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six participants were enrolled, and all were infective to mosquitoes before tafenoquine, with a median 86% (range, 22\u201398) of mosquitoes positive for oocysts and 57% (range, 4\u201392) positive for sporozoites. By day 4 after tafenoquine, the oocyst and sporozoite positivity rate had reduced by a median 35% (interquartile range [IQR]: 16\u201346) and 52% (IQR: 40\u201362), respectively, and by day 7, 81% (IQR 36\u201392) and 77% (IQR 52\u201398), respectively. The decline in gametocyte density after tafenoquine was not significant. No significant participant safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Low-dose tafenoquine (50 mg) reduces P. falciparum transmission to mosquitoes, with a delay in effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciac503","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T13:42:30Z","timestamp":1655905350000},"page":"506-512","source":"Crossref","is-referenced-by-count":12,"title":["Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With\n                    <i>Plasmodium falciparum<\/i>"],"prefix":"10.1093","volume":"76","author":[{"given":"Rebecca","family":"Webster","sequence":"first","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Mitchell","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M","family":"Peters","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanita","family":"Heunis","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brighid","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Gower","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Lynch","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Jennings","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona H","family":"Amante","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Marquart","sequence":"additional","affiliation":[{"name":"The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Potter","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey W","family":"Birrell","sequence":"additional","affiliation":[{"name":"Australian Defence Force Malaria and Infectious Disease Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Edstein","sequence":"additional","affiliation":[{"name":"Australian Defence Force Malaria and Infectious Disease Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Dennis","family":"Shanks","sequence":"additional","affiliation":[{"name":"Australian Defence Force Malaria and Infectious Disease Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"McCarthy","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"},{"name":"The Peter Doherty Institute for Infection and Immunity , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-7960","authenticated-orcid":false,"given":"Bridget E","family":"Barber","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"2023020817075341200_ciac503-B1","volume-title":"World Malaria Report","year":"2020"},{"key":"2023020817075341200_ciac503-B2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.pt.2018.07.001","article-title":"Antimalarial transmission-blocking interventions: past, present, and future","volume":"34","author":"Delves","year":"2018","journal-title":"Trends Parasitol"},{"key":"2023020817075341200_ciac503-B3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.pt.2022.01.011","article-title":"Transmission-blocking drugs for malaria elimination","volume":"38","author":"Birkholtz","year":"2022","journal-title":"Trends Parasitol"},{"key":"2023020817075341200_ciac503-B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0035-9203(00)90447-4","article-title":"The mosquito transmission of malaria: the effects of atovaquone-proguanil (Malarone) and chloroquine","volume":"94","author":"Enosse","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2023020817075341200_ciac503-B5"},{"key":"2023020817075341200_ciac503-B6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1473-3099(18)30044-6","article-title":"Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial","volume":"18","author":"Dicko","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023020817075341200_ciac503-B7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","article-title":"Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Goncalves","year":"2016","journal-title":"BMC Med"},{"key":"2023020817075341200_ciac503-B8","doi-asserted-by":"crossref","first-page":"e0006230","DOI":"10.1371\/journal.pntd.0006230","article-title":"Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries","volume":"12","author":"Recht","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2023020817075341200_ciac503-B9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2125.1984.tb02369.x","article-title":"Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite","volume":"17","author":"Mihaly","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"2023020817075341200_ciac503-B10","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: first global approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"2023020817075341200_ciac503-B11","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1128\/AAC.01183-06","article-title":"Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects","volume":"51","author":"Charles","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020817075341200_ciac503-B12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.0306-5251.2001.01482.x","article-title":"Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers","volume":"52","author":"Edstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2023020817075341200_ciac503-B13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QCO.0000000000000574","article-title":"Tafenoquine: the new kid on the block","volume":"32","author":"Chen","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"2023020817075341200_ciac503-B14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4269\/ajtmh.1992.46.169","article-title":"Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes","volume":"46","author":"Coleman","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"2023020817075341200_ciac503-B15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpddr.2017.03.002","article-title":"Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum","volume":"7","author":"Kemirembe","year":"2017","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2023020817075341200_ciac503-B16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4269\/ajtmh.2003.69.542","article-title":"Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand","volume":"69","author":"Ponsa","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"2023020817075341200_ciac503-B17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.vetpar.2016.12.008","article-title":"Artesunate-tafenoquine combination therapy promotes clearance and abrogates transmission of the avian malaria parasite Plasmodium gallinaceum","volume":"233","author":"Tasai","year":"2017","journal-title":"Vet Parasitol"},{"key":"2023020817075341200_ciac503-B18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/acs.biochem.9b01105","article-title":"Tafenoquine: a step toward malaria elimination","volume":"59","author":"Lu","year":"2020","journal-title":"Biochemistry"},{"key":"2023020817075341200_ciac503-B19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers","volume":"97","author":"Rueangweerayut","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2023020817075341200_ciac503-B20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(19)30611-5","article-title":"Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a\/b trial","volume":"20","author":"Gaur","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023020817075341200_ciac503-B21","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/jac\/dkw174","article-title":"Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers","volume":"71","author":"McCarthy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023020817075341200_ciac503-B22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023020817075341200_ciac503-B23","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/AAC.02883-15","article-title":"Linking murine and human Plasmodium falciparum challenge models in a translational path for antimalarial drug development","volume":"60","author":"McCarthy","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020817075341200_ciac503-B24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","article-title":"Safety, pharmacokinetics, and antimalarial activity of the novel Plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023020817075341200_ciac503-B25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI98012","article-title":"A controlled human malaria infection model enabling evaluation of transmission-blocking interventions","volume":"128","author":"Collins","year":"2018","journal-title":"J Clin Invest"},{"key":"2023020817075341200_ciac503-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-10-48","article-title":"A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers","volume":"10","author":"Rockett","year":"2011","journal-title":"Malar J"},{"key":"2023020817075341200_ciac503-B27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12936-020-03291-9","article-title":"Assays for quantification of male and female gametocytes in human blood by qRT-PCR in the absence of pure sex-specific gametocyte standards","volume":"19","author":"Wang","year":"2020","journal-title":"Malar J"},{"key":"2023020817075341200_ciac503-B28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4269\/ajtmh.16-0893","article-title":"Molecular markers for sensitive detection of Plasmodium falciparum asexual stage parasites and their application in a malaria clinical trial","volume":"97","author":"Tadesse","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2023020817075341200_ciac503-B29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiw128","article-title":"Piperaquine monotherapy of drug-susceptible Plasmodium falciparum infection results in rapid clearance of parasitemia but is followed by the appearance of gametocytemia","volume":"214","author":"Pasay","year":"2016","journal-title":"J Infect Dis"},{"key":"2023020817075341200_ciac503-B30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12936-018-2382-6","article-title":"Assessing Plasmodium falciparum transmission in mosquito-feeding assays using quantitative PCR","volume":"17","author":"Wang","year":"2018","journal-title":"Malar J"},{"key":"2023020817075341200_ciac503-B31","author":"Linden"},{"key":"2023020817075341200_ciac503-B32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","article-title":"Repeated measures correlation","volume":"8","author":"Bakdash","year":"2017","journal-title":"Front Psychol"},{"key":"2023020817075341200_ciac503-B33"},{"key":"2023020817075341200_ciac503-B34","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2666-5247(21)00356-6","article-title":"Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial","volume":"3","author":"Stone","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023020817075341200_ciac503-B35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1084\/jem.173.3.523","article-title":"Cytokines kill malaria parasites during infection crisis: extracellular complementary factors are essential","volume":"173","author":"Naotunne","year":"1991","journal-title":"J Exp Med"},{"key":"2023020817075341200_ciac503-B36","first-page":"555","article-title":"Cytokine-mediated inactivation of malarial gametocytes is dependent on the presence of white blood cells and involves reactive nitrogen intermediates","volume":"78","author":"Naotunne","year":"1993","journal-title":"Immunology"},{"key":"2023020817075341200_ciac503-B37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12936-021-04003-7","article-title":"Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria","volume":"20","author":"Woolley","year":"2021","journal-title":"Malar J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac503\/45033864\/ciac503.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/506\/49125096\/ciac503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/506\/49125096\/ciac503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T12:43:21Z","timestamp":1675860201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/3\/506\/6613332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6,22]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac503","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.15.22272229","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,6,22]]}}}